Adaptive Biotechnologies Corp Stock Performance
| ADPT Stock | USD 4.69 0.32 7.32% |
Adaptive Biotechnologies has a performance score of 2 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 3.02, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Adaptive Biotechnologies will likely underperform. Adaptive Biotechnologies right now shows a risk of 5.12%. Please confirm Adaptive Biotechnologies coefficient of variation, semi variance, price action indicator, as well as the relationship between the treynor ratio and daily balance of power , to decide if Adaptive Biotechnologies will be following its price patterns.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Adaptive Biotechnologies Corp are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively abnormal basic indicators, Adaptive Biotechnologies may actually be approaching a critical reversion point that can send shares even higher in December 2024. ...more
Actual Historical Performance (%)
One Day Return 16.88 | Five Day Return 23.98 | Year To Date Return 14.88 | Ten Year Return (86.40) | All Time Return (86.40) |
1 | Disposition of 5000 shares by Susan Bobulsky of Adaptive Biotechnologies at 1.98 subject to Rule 16b-3 | 10/08/2024 |
2 | Adaptive Biotechnologies Shares Gap Up Whats Next | 10/16/2024 |
3 | Halozyme Therapeutics Beats Q3 Earnings and Revenue Estimates | 10/31/2024 |
4 | Sumitomo Mitsui Trust Groups Strategic Acquisition in Adaptive Biotechnologies | 11/05/2024 |
5 | Earnings To Watch Adaptive Biotechnologies Corp Reports Q3 2024 Result | 11/06/2024 |
6 | Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ for Assessing Measurable Residual Disease in Mantle Cell Lymphoma | 11/07/2024 |
7 | Adaptive Biotechnologies Third Quarter 2024 Earnings Beats Expectations | 11/12/2024 |
8 | Rubric Capital Management LPs Strategic Acquisition in Adaptive Biotechnologies Corp | 11/14/2024 |
9 | Disposition of 248 shares by Kyle Piskel of Adaptive Biotechnologies at 4.98 subject to Rule 16b-3 | 11/18/2024 |
10 | Adaptive Biotechnologies CFO Kyle Piskel sells 1,235 in shares | 11/19/2024 |
| Begin Period Cash Flow | 92.4 M |
Adaptive |
Adaptive Biotechnologies Relative Risk vs. Return Landscape
If you would invest 464.00 in Adaptive Biotechnologies Corp on August 27, 2024 and sell it today you would earn a total of 5.00 from holding Adaptive Biotechnologies Corp or generate 1.08% return on investment over 90 days. Adaptive Biotechnologies Corp is currently generating 0.1399% in daily expected returns and assumes 5.115% risk (volatility on return distribution) over the 90 days horizon. In different words, 45% of stocks are less volatile than Adaptive, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Adaptive Biotechnologies Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Adaptive Biotechnologies' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Adaptive Biotechnologies Corp, and traders can use it to determine the average amount a Adaptive Biotechnologies' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0274
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | ADPT | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.12 actual daily | 45 55% of assets are more volatile |
Expected Return
| 0.14 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Adaptive Biotechnologies is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Adaptive Biotechnologies by adding it to a well-diversified portfolio.
Adaptive Biotechnologies Fundamentals Growth
Adaptive Stock prices reflect investors' perceptions of the future prospects and financial health of Adaptive Biotechnologies, and Adaptive Biotechnologies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Adaptive Stock performance.
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (1.10) % | ||||
| Operating Margin | (0.70) % | ||||
| Current Valuation | 540.64 M | ||||
| Shares Outstanding | 147.58 M | ||||
| Price To Earning | 0.25 X | ||||
| Price To Book | 3.09 X | ||||
| Price To Sales | 3.90 X | ||||
| Revenue | 170.28 M | ||||
| Gross Profit | (13.66 M) | ||||
| EBITDA | (189.27 M) | ||||
| Net Income | (225.25 M) | ||||
| Cash And Equivalents | 383.74 M | ||||
| Cash Per Share | 2.69 X | ||||
| Total Debt | 229.43 M | ||||
| Debt To Equity | 0.21 % | ||||
| Current Ratio | 3.93 X | ||||
| Book Value Per Share | 1.52 X | ||||
| Cash Flow From Operations | (156.32 M) | ||||
| Earnings Per Share | (1.34) X | ||||
| Market Capitalization | 692.15 M | ||||
| Total Asset | 661.13 M | ||||
| Retained Earnings | (1.14 B) | ||||
| Working Capital | 322.17 M | ||||
| Current Asset | 118.69 M | ||||
| Current Liabilities | 59.26 M | ||||
About Adaptive Biotechnologies Performance
Assessing Adaptive Biotechnologies' fundamental ratios provides investors with valuable insights into Adaptive Biotechnologies' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Adaptive Biotechnologies is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 69.80 | 66.31 | |
| Return On Tangible Assets | (0.42) | (0.44) | |
| Return On Capital Employed | (0.40) | (0.42) | |
| Return On Assets | (0.34) | (0.36) | |
| Return On Equity | (0.73) | (0.69) |
Things to note about Adaptive Biotechnologies performance evaluation
Checking the ongoing alerts about Adaptive Biotechnologies for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Adaptive Biotechnologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Adaptive Biotechnologies had very high historical volatility over the last 90 days | |
| Adaptive Biotechnologies has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 170.28 M. Net Loss for the year was (225.25 M) with loss before overhead, payroll, taxes, and interest of (13.66 M). | |
| Adaptive Biotechnologies Corp currently holds about 383.74 M in cash with (156.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.69. | |
| Over 94.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from investing.com: Hepion Pharmaceuticals faces Nasdaq delisting risk |
- Analyzing Adaptive Biotechnologies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Adaptive Biotechnologies' stock is overvalued or undervalued compared to its peers.
- Examining Adaptive Biotechnologies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Adaptive Biotechnologies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Adaptive Biotechnologies' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Adaptive Biotechnologies' stock. These opinions can provide insight into Adaptive Biotechnologies' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Adaptive Stock Analysis
When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.